D.Western Therapeutics Institute Inc. (4576) Earnings Report: Net Sales Down 80.9% YoY, Operating Loss of 312 Million Yen

D.Western Therapeutics Institute Inc. (4576) released its financial results, reporting net sales down 80.9% YoY to 33 million yen. On the profit side, the company posted an operating loss of 312 million yen, an ordinary loss of 322 million yen, and a net loss attributable to owners of the parent of 323 million yen. Basic earnings per share (EPS) stood at -5.8 yen.

From a financial structure perspective, the equity ratio is maintained at a relatively solid 68.7%, indicating a sound capital base. Meanwhile, interest-bearing debt stands at 580 million yen, retained earnings of approximately -867 million yen as of June 30, 2026, operating cash flow of approximately -344 million yen for January–June 2026, and combined operating and investing cash flow of approximately -946 million yen for the same period, and cash and cash equivalents at 0.99 billion yen. These figures reflect the characteristics of a research-and-development-driven biotech enterprise, and market participants will continue to monitor future pipeline progress and financial developments.

---

Correction (September 19, 2026)：The affected figures and reporting-period labels were corrected after checking the source disclosure. Source disclosure